USA – Johnson & Johnson Consumer Inc. is set to present new research highlighting important advances in the understanding and treatment of skin at the 2022 American Academy of Dermatology (AAD) Meeting, taking place in Boston.
A total of 11 posters ranging from the effects of oat against environmental and anti-inflammatory triggers to a vitamin C serum with clinical benefits across diverse skin types will be presented at this year’s meeting.
“At Johnson & Johnson Consumer Health, we take pride in the breadth of our scientific solutions for healthier skin, which continue to evolve as the world around us does,” said Caroline Tillett, Global Head R&D, Johnson & Johnson Consumer Health.
“In the past year, and through our critical research programs, we’re addressing consumer health needs across various skin states and types, including aging, sensitive, and hyperpigmented skin.
Our new research—concerning external factors impacting skin such as environmental triggers and mental stress—demonstrates our commitment to innovating far beyond the visible layer.”
Grounded in science, Johnson & Johnson Consumer Health brings leading skincare products to consumers and healthcare professionals globally.
Its recent skincare innovations include the Neutrogena Rapid Wrinkle Repair Retinol Pro+ .5% Power Serum, an anti-aging facial serum that contains the brand’s highest concentration of 0.5% pure retinol in a skin-nourishing serum.
Other recent innovations include the AVEENO Calm + Restore line which helps restore the skin’s moisture barrier with nourishing prebiotic oat, the Neutrogena Stubborn line, which provides dermatologist-grade over-the-counter treatments for acne-prone and hyperpigmented skin.
Also making it to the list of recent Johnson & Johnson’s skincare innovations is Exuviance Age Reverse + Rebuild-5 formulated with 5 rejuvenating ingredients, including MicroDiPeptide229, for visibly firmer skin in just two weeks.
Pursuing more targeted growth strategies
Johnson & Johnson announced in November last year that it will form a new publicly traded company to handle its consumer health business as part of its wider plan to pursue more targeted growth strategies, continuing a trend among the largest firms in the pharmaceutical industry.
This was a significant step for J&J, which has become synonymous with brands like Neutrogena, Aveeno, Tylenol, Listerine, Band-Aid, and Johnson & Johnson’s Baby Powder.
These brands, along with the well-known allergy medication Zyrtec, will power the new company.
Similar initiatives have been undertaken by companies such as Merck, Sanofi, Pfizer, and GlaxoSmithKline, which have separated their consumer health products in order to focus on the highly profitable pharmaceutical business.
The industry trend of major corporations separating their consumer health units gained traction in 2018 when several companies made such moves. J&J, on the other hand, doubled down on staying together the following year.
Rather than sell, it agreed to pay 230 billion Japanese yen (US$2.0 billion) for the remaining share of Japanese cosmetics and skincare specialist Ci:z.
J&J’s popular medical cosmetic products Dr. Ci: Labo, Labo Labo, and Genomer gained additional clout in Japan and other Asian markets as a result of the acquisition.
Furthermore, rather than separating consumer and pharma, J&J merged the two divisions in June under the leadership of former pharma chief Duato.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE